Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared a post on LinkedIn:
“Oliver Soehnlein led our update on inflammation in atherosclerosis and the opportunities for novel therapies to quench the smoldering within the plaque and improve clinical outcomes. Table 1 features “Emerging preclinical interference strategies aimed at reducing atherosclerosis” and Figure 5 presents a “Timeline of major milestones of research connecting inflammation with atherosclerosis” which we hope ongoing studies and clinical trials will soon extend as we seek the “sweet spot” of calming inflammation while avoiding undue interference with host defenses or tumor surveillance. Libby and Soehnlein, Inflammation in atherosclerosis: Lessons and therapeutic implications, Immunity (2025),”
Title: Inflammation in atherosclerosis: Lessons and therapeutic implications
Authors: Peter Libby, Oliver Soehnlein
Read full article here.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 23:57N. Mariana S. Vasquez: TTP vs ITP vs DIC
-
Aug 26, 2026, 23:49Mauricio Ambriz: Pathogenesis of Autoimmune Hemolytic Anemia Mediated by Warm and Cold Antibodies
-
Aug 26, 2026, 23:45Can Thromboinflammation Biomarkers Improve PE Mortality Prediction? – RPTH Journal
-
Aug 26, 2026, 23:44From Almost Universally Fatal to Largely Treatable iTTP – American Society of Hematology
-
Aug 26, 2026, 23:39Eric Topol: Shingles Vaccine Associated with 10% Drop in Heart Failure and Stroke
-
Aug 26, 2026, 22:59Debbe McCall: Should Frail Elderly Patients Stable on Warfarin Switch to DOACs?
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
-
Aug 26, 2026, 18:24New Educational Content for the Bleeding Disorders Community – EAHAD